SUNNYVALE, Calif., Dec. 4, 2019 /PRNewswire/ -- Accuray Incorporated
(NASDAQ: ARAY) announced today that Stanford
University Medical Center has selected a second
CyberKnife® M6™ System to expand access to precise
radiosurgery treatments to more of their patients. With its
installation, the hospital's clinicians will have a CyberKnife
System dedicated to the treatment of diseases in the brain and base
of the skull, making it possible for the existing system to be used
to treat more patients with tumors elsewhere in the body. The new
CyberKnife System will be installed at the Stanford Neuroscience
Health Center, a comprehensive facility offering integrated
outpatient services in one location designed to provide more
accurate diagnoses, organized care, better quality of life and
improved outcomes for the patient.
"We value our long-standing partnership with the Stanford clinical team, one of the most respected
in the world, and are proud that they are using the CyberKnife
System to improve the outcomes of people diagnosed with serious
medical conditions," said Joshua H.
Levine, president and CEO at Accuray. "At Accuray, our goal
is to provide clinicians with a system that makes it as easy as
possible for them to provide the best possible outcome for their
patients, based on each patient's unique condition. Over the course
of our relationship with the Stanford
team, they have acquired four CyberKnife Systems, reinforcing their
continued confidence in the system and demonstrating that we are
delivering on our goal."
"This year marks 25 years since
the world's first patient was treated with a prototype CyberKnife
System at Stanford. While clinicians at
our hospital have used some version of the system since that time,
a dedicated system located in our neuroscience center will enable
us to provide precise and accurate SRS treatments to significantly
more patients," said Steven D.
Chang, MD, Co-Director, Stanford Surgical Neuro-Oncology
Program, Co-Director, Stanford CyberKnife Program, Stanford University School of Medicine. "The
introduction of the CyberKnife System changed the way diseases or
tumors in the head are treated. The system established
multi-session or fractionated treatment as a standard for cranial
stereotactic radiosurgery, a technique that has brought meaningful
benefits to patients and the medical field."
The CyberKnife System was designed to deliver stereotactic
radiosurgery (SRS) without a rigid frame bolted to the
patient's head, which some other systems use to prevent movement
during treatment. It provides a precise and effective option for
patients with diseases or tumors in the brain requiring single or
multi-session treatments, and younger patients who would not be
candidates for treatment with a fixed head frame. Since its
introduction, advanced new functionality, including the VOLO™
Optimizer, has been added to the CyberKnife System, enabling
clinicians to treat patients significantly faster, without
sacrificing the precision or accuracy for which the system is
known.
SRS typically involves the delivery of a single high-dose
radiation treatment or a few fractionated radiation treatments
(usually up to five treatments) to destroy all tissue within the
tumor. The ability to deliver high doses of radiation in a single
or a few fractions is called hypofractionation. Hypofractionation
can only be undertaken with systems that are able to target the
tumor with extreme precision and accuracy, as the CyberKnife System
can, while minimizing delivered dose to surrounding healthy tissue.
The CyberKnife System has been proven to deliver radiation to the
skull with sub-millimeter accuracy (to within 1.0mm of the
target)1, meaning minimal radiation is delivered to the
surrounding healthy brain tissue.
The CyberKnife System is routinely used to treat conditions in
the brain including, but not limited to, benign and malignant
primary tumors, brain metastases, trigeminal neuralgia, acoustic
neuromas and arteriovenous malformations (AVMs). CyberKnife
radiosurgery is even used to treat complicated neurosurgical cases,
while maximally sparing brain tissues involved in important
functions such as hearing and vision.
About the CyberKnife® System
The CyberKnife System is the only robotic radiosurgery system that
offers highly precise, non-surgical treatment for tumors and
lesions anywhere in the body—including the brain, breast, kidney,
liver, lung, pancreas, prostate and spine. The CyberKnife System
tracks and automatically adjusts for tumor or patient movement
during treatment, delivering the radiation dose directly to the
target with sub-millimeter precision. Synchrony® motion
tracking and correction technology expands on the CyberKnife
System's unique motion synchronization capabilities to provide
additional precision when treating tumors that move with
respiration. The high level of accuracy in dose delivery made
possible by the system gives clinical teams the confidence to
deliver state-of-the-art treatments for a wide range of cancers and
functional disorders, without sacrificing patients' quality of
life.
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences, and patient outcomes. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the company's ability to achieve widespread
market acceptance of its products, including new product offerings
and improvements; the company's ability to develop new products or
improve existing products to meet customers' needs; the company's
limited long-term clinical data supporting the safety and efficacy
of its products, including product improvements, for certain users
and such other risks identified under the heading "Risk Factors" in
the company's quarterly report on Form 10-Q, filed with the
Securities and Exchange Commission (the "SEC") on November 6, 2019 and as updated periodically with
the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contacts
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jayme Maniatis
MSLGROUP
+1 (781) 684-6610
accuray@mslgroup.com
1 Antypas et al. Physics in Medicine and
Biology.53;(2008)4697-4718. Performance Evaluation of a CyberKnife®
G4 image-guided robotic stereotactic radiosurgery system
View original content to download
multimedia:http://www.prnewswire.com/news-releases/stanford-university-medical-center-to-acquire-second-accuray-cyberknife-m6-system-300968844.html
SOURCE Accuray Incorporated